The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.
While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.
Combination therapy with elexacaftor/tezacaftor/ivacaftor resulted in clinically significant improvements in lung function in patients with cystic fibrosis.
Investigators sought to determine whether resistance to antibiotic treatment was associated with failed eradication therapy in patients with cystic fibrosis.
Lumacaftor-ivacaftor is generally safe and well tolerated for long-term treatment of children with cystic fibrosis homozygous for the F508del-CFTR mutation.
Digital tomosynthesis of the chest offers effective quantitative estimation of structural lung disease in patients with cystic fibrosis.
Bronchitol should only be used by adults who have passed the Bronchitol Tolerance Test.
Clinicians across multiple disciplines largely accepted telehealth in the cystic fibrosis care model during the COVID-19 pandemic.